HeartFlow Stock $7.28

Forge Price BeaconForge Price 1 updated November 17, 2024

heartflow.comHealthcare / Healthcare providers & servicesFounded: 2007Funding to Date: $528.72MM

HeartFlow is revolutionizing precision heart care, combining human ingenuity with advanced AI technology. They began their journey to improve coronary artery disease diagnosis with FFRCT and have now expanded their product portfolio to include anatomic stenosis and plaque information. This company was founded by Charles Taylor, Christopher Zarins, and John Stevens in 2007 and is headquartered in Redwood City, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for HeartFlow, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

HeartFlow Stock Price

3M
6M
1Y
MAX
Forge Price 1
Date
11/17/2024
Price per Share
$7.28
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

HeartFlow Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
06/13/2019 Series E $305MM $xx.xx $1.65B Wellington Management, Baillie Gifford
Price per Share
$xx.xx
Shares Outstanding
13,422,649
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Wellington Management, Baillie Gifford
05/10/2016 Series D $99.93MM $xx.xx $771.66MM Panorama Point Partners, BlueCross BlueShield Venture Partners, undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
7,151,873
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Panorama Point Partners, BlueCross BlueShield Venture Partners, undisclosed investors
02/26/2014 Series C $104.7MM $xx.xx $373.44MM Sandbox Industries, HealthCor Management, Capricorn Investment Group, undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
11,343,434
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sandbox Industries, HealthCor Management, Capricorn Investment Group, undisclosed investors
02/04/2011 Series B-2 $10.11MM $xx.xx $90.13MM HealthCor Partners Management, GE Ventures, undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
2,848,263
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
HealthCor Partners Management, GE Ventures, undisclosed investors
02/04/2011 Series B-1 $6.94MM $xx.xx $90.13MM HealthCor Partners Management, GE Ventures, undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
1,954,846
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
HealthCor Partners Management, GE Ventures, undisclosed investors
04/16/2010 Series A $2.04MM $xx.xx $8.17MM Emergent Medical Partners, U.S. Venture Partners, BlueCross BlueShield Venture Partners, Capricorn Healthcare, Special Opportunities
Price per Share
$xx.xx
Shares Outstanding
4,082,965
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Emergent Medical Partners, U.S. Venture Partners, BlueCross BlueShield Venture Partners, Capricorn Healthcare, Special Opportunities

HeartFlow investors also invested in these private companies

Leadership & Board

Leadership

Campbell Rogers MD
Chief Medical Officer & Executive Vice President
Charles Taylor Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Noemi Espinosa JD
Chief Ethics & Compliance Officer & General Counsel
Christopher Zarins MD
Co-Founder, Senior Advisor on Clinical Science & Senior Vice President of Medical Affairs
John Farquhar
Chief Executive Officer, President & Board Member
Monica Tellado
Chief Financial Officer

Board

Jeffrey Lightcap
HealthCor Partners Management
Casey Tansey
US Venture Partners
Barry Uphoff
Capricorn Investment Group

HeartFlow stock FAQs

plusminus

Can you buy HeartFlow stock?

As HeartFlow is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like HeartFlow, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy HeartFlow stock?

To invest in a private company like HeartFlow through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell HeartFlow stock?

Yes, you may sell the HeartFlow stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell HeartFlow stock?

If you hold private company shares of HeartFlow – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your HeartFlow on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is HeartFlow a public company?

No, HeartFlow is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is HeartFlow’s stock price?

HeartFlow is a private company, meaning it does’t have a publicly traded stock price. However, as of 11/17/2024 the HeartFlow Forge Price is $7.28 per share. The Forge Price is a derived price calculated for private companies like HeartFlow to provide insights into their current valuation. Learn more about Forge Price.
plusminus

What is HeartFlow’s stock ticker symbol?

HeartFlow does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

HeartFlow’s news and media highlights

UHS' Cardiovascular Imaging team earned a prestigious HeartFlow CT Quality Award for Q2 2023, placing them in the top 20% globally for quality and adoption of cardiovascular imaging. This recognition highlights UHS' leadership in providing advanced cardiac imaging services through CT scans, MRI, and nuclear imaging.
HeartFlow, a leader in AI-enabled cardiac diagnostics, announced reaching 250,000 patients assessed with its FFRCT technology. This milestone comes alongside new product launches, positioning HeartFlow to further grow its comprehensive portfolio for precision coronary care.
For 2019, we asked companies around the world one basic question: “Please indicate the key technology which you believe will have the most profound impact on the healthcare industry during 2019?” The results are not very surprising:
The $1.5 billion health-tech startup HeartFlow has a noninvasive test for heart disease based on machine learning analysis of CT scans. Two new studies are unlikely to win over its critics.
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.